Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 14/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 14/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 11/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 11/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 11/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16653687 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL16653688 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL1531609 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL1531623 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL13734679 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL25189379 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL15874738 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL25263000 | 0.85 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL30988171 | 0.84 | ATM (0.46) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL30988157 | 0.84 | ATM (0.46) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024035688-A1 | MACROCYCLIC BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| WO-2023211256-A1 | NOVEL PIM KINASE INHIBITORS AND USES THEREOF | 제일약품주식회사 | 2023-11-02 | — | — | WO | disclosed |
| EP-4186897-A1 | PYRIDINECARBOXAMIDE COMPOUND USEFUL AS PIM KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-3670506-B1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE HOLDINGS CORP (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-108699032-B | Polycyclic TLR7/8 antagonists and their use in the treatment of immune disorders | 默克专利有限公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | INCYTE CORPORATION (US) | 2022-01-25 | — | — | US | disclosed |
| CN-113603675-A | Polycyclic TLR7/8 antagonists and their use in the treatment of immune disorders | 默克专利有限公司 | 2021-11-05 | — | — | CN | disclosed |
| US-10968203-B2 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders | GENENTECH, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200405702-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2020-12-31 | — | — | US | disclosed |
| US-10828290-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | INCYTE CORPORATION (US) | 2020-11-10 | — | — | US | disclosed |
| EP-2945939-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | Incyte Corporation (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150329534-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION | 2015-11-19 | — | — | US | disclosed |
| WO-2015057655-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015027124-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | WO | disclosed |
| US-20150057265-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | US | disclosed |
| WO-2014113388-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2014-07-24 | — | — | WO | disclosed |
| US-20140200227-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140200216-A1 | BICYCLIC AROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2014-07-17 | — | — | US | disclosed |
| US-8735424-B2 | Bicyclic kinase inhibitors | NOVARTIS AG (CH) | 2014-05-27 | — | — | US | disclosed |
| WO-2010026121-A1 | BICYCLIC KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200216-A1 | BICYCLIC AROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | CHRNB2 4482/4885CHRNA4 4315/4885CHRNA7 3876/4885 |
| US-20150329534-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM2, PIM1, PIM3 | CHRNB2 4767/4885CHRNA4 4585/4885CHRNA7 4487/4885 |
| US-10968203-B2 | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders | XBP1, ERN1, ATF4 | CHRNB2 3759/4885CHRNA4 3829/4885CHRNA7 4205/4885 |
| US-20200405702-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM2, PIM1, PIM3 | CHRNB2 4767/4885CHRNA4 4585/4885CHRNA7 4487/4885 |
| US-11229631-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors | PIM2, PIM1, PIM3 | CHRNB2 4767/4885CHRNA4 4585/4885CHRNA7 4487/4885 |
| US-10828290-B2 | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | PIM2, PIM1, PIM3 | CHRNB2 4767/4885CHRNA4 4585/4885CHRNA7 4487/4885 |
| US-20150057265-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | CHRNB2 4721/4885CHRNA4 4590/4885CHRNA7 4495/4885 |
| US-20140200227-A1 | THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | PIM2, PIM1, PIM3 | CHRNB2 4767/4885CHRNA4 4585/4885CHRNA7 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.